Novartis Starts Investigation On China Bribery Allegations; SAIC Initiates Crackdown On Illegal Competition
This article was originally published in PharmAsia News
Executive Summary
A Novartis sales representative in China has gone on record about fees given to doctors in exchange for prescriptions of a Novartis cancer therapy. Meanwhile, China’s State Administration for Industry and Commerce (SAIC) has started a three-month long enforcement campaign with a focus on pharmaceutical marketing and medical service.
You may also be interested in...
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.